


MDH-313 for the Treatment of Solid Cancers

MDH-313 (*Leuconostoc mesenteroides* EV) is a new class of first-in-class oral & systemic nanotherapeutic indicated for intractable solid cancers, such as colorectal, lung, gastric, pancreatic cancers, and more

MDH-313

- Naïve (natural) EVs from a single **Leuconostoc** strain



Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a newly discovered, safe bacterium *Leuconostoc mesenteroides*-derived EVs
3. **Effective**: an immune and metabolic dysfunction-modulating therapy against intractable solid cancers
4. **Convenient administration**: orally- as well as systemically-delivered
5. **Affordable**: cost effective production

MDH-313: Key Indications & Development Timeline

Key Indications

- 1) **Colorectal cancer (CRC)**
- 2) **Gastric cancer (GC)**
- 3) **Non small cell lung cancer (NSCLC)**
- 4) **Hepatocellular cancer (HCC)**
- 5) **Pancreatic cancer (PC)**

Core patent

- ✓ PCT application date at 02/Jun/2022
- ✓ Key indications:
 - 1) Inflammatory diseases
 - 2) Cancers

Development Timeline

IND filing ('24)



P1 ('25)



P2 ('27)



Exit